本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 证券代码：002496 证券简称：辉丰股份 公告编号：2025-002 一、公司股票交易可能被实施退市风险警示的原因 江苏辉丰生物农业股份有限公司 经江苏辉丰生物农业股份有限公司（以下简称"公司"）财务部门初步测算， 预计2024年度经审计的净利润为负值且扣除后营业收入存在低于3亿元的可能， 具体内容详见公司已披露的《2024 年度业绩预告》（公告编号：2025-001）。 关于公司股票可能被实施退市风险警示的提示性公告 公司 2024 年年度报告披露后，若最近一个会计年度经审计的净利润为负值 且营业收入低于 3 亿元（上述净利润以扣除非经常性损益前后孰低者为准；营业 收入应当扣除与主营业务无关的业务收入和不具备商业实质的收入），根据《深 圳证券交易所股票上市规则》第 9.3.1 条规定，公司股票交易可能被实施退市 风险警示（股票简称前冠以"*ST"字样）。 为充分提示以上风险，根据《深圳证券交易所股票上市规则》9.3.2 条规定， 公司将在披露 2024 年年度报告前至少再披露两次风险提示公告。 二、其他事项 ...

Financial Performance Expectations - The company expects a net profit attributable to shareholders of between -150 million to -180 million yuan, a reduction in losses of 61.48% to 67.90% compared to the previous year's loss of 467.32 million yuan [3]. - The net profit after deducting non-recurring gains and losses is expected to be between -180 million to -220 million yuan, a reduction in losses of 48.73% to 58.05% compared to the previous year's loss of 429.08 million yuan [3]. Revenue Projections - The expected operating revenue is between 280 million to 360 million yuan, an increase from 231.11 million yuan in the same period last year [3]. - The expected operating revenue after deductions is between 260 million to 340 million yuan, up from 211.04 million yuan in the previous year [3]. Reasons for Expected Losses - The company cites reasons for the expected losses including underperformance during the transformation phase, losses from changes in fair value of financial assets, and significant losses from the joint venture, Ando麦辉丰 (Jiangsu) Co., Ltd. [5].

证券代码：002496 证券简称：辉丰股份 公告编号：2024-035 江苏辉丰生物农业股份有限公司 关于公司诉讼事项的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、本次诉讼事项受理的基本情况 江苏辉丰生物农业股份有限公司于近日收到江苏省盐城市中级人民法院送 达的《受理案件通知书》（2024）苏 09 民初 61 号。 二、诉讼事项的基本情况 四、本次公告的诉讼对公司本期利润或后期利润的可能影响 目前本次诉讼尚未开庭审理，最终判决结果对公司本期利润或后期利润的影 响存在不确定性，敬请投资者注意投资风险。 五、备查文件 被告：北京航天石化技术装备工程有限公司（简称"北京航天"）。 2、案由。承揽合同纠纷。 3、请求事项。依法判令被告继续履行案涉合同和协议，限期进行维修整改， 完成竣工验收。依法判令被告赔偿因固废焚烧炉不能正常运行导致原告委外处置 产生的损失 16342.4426 万元。本案的诉讼费用由被告负担。 4、事实与理由。2016 年 7 月 22 日，公司与北京航天签订固体废弃物项目 EPC(除土建)总承包合同及技术协议。然而北京航天承揽的项 ...

证券代码：002496 证券简称：辉丰股份 公告编号：2024-034 江苏辉丰生物农业股份有限公司 关于收到民事判决书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 江苏辉丰生物农业股份有限公司（以下简称"公司"、"辉丰股份"）于近日收到河北省 赵县人民法院出具的《民事判决书》(2023)冀 0133 民初 3582 号，现将有关情况公告如下： 一、案件基本情况 瑞凯公司解散纠纷，详见公司于 2024 年 1 月 2 日在《上海证券报》、《证券时报》和巨 潮资讯网披露的《关于公司诉讼事项的公告》，公告编号为 2023-045）。 二、案件判决情况 判决如下：解散石家庄瑞凯化工有限公司。 三、是否有其他尚未披露的诉讼仲裁事项 截至本公告日，公司无应披露而未披露的其他重大诉讼、仲裁事项。 四、本次公告的诉讼、仲裁对公司本期利润或期后利润的可能影响 本案件为公司解散纠纷，判决结果对公司本期利润或期后利润的影响存在不确定性，敬请 投资者注意投资风险。 （一）案件当事人 原告：江苏辉丰生物农业股份有限公司 被告：石家庄瑞凯化工有限公司 第三人：河北佰事达商贸有 ...

Financial Performance - Revenue for Q3 2024 reached ¥43,442,264.59, an increase of 12.85% compared to the same period last year[2] - Net profit attributable to shareholders was -¥33,454,955.85, a decrease of 37.35% year-on-year[2] - Net profit excluding non-recurring items was -¥39,127,569.87, a decrease of 38.31% compared to the previous year[2] - Total operating revenue for Q3 2024 was ¥153,558,410.52, a decrease of 4.25% from ¥160,924,928.94 in the same period last year[16] - The company's operating profit was -196,321.84 CNY, a significant improvement from -112,892,932.57 CNY in Q3 2023[17] - The total comprehensive income for the period was 1,418,799.97 CNY, a recovery from -105,683,021.05 CNY in Q3 2023[18] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,578,638,790.83, down 6.21% from the end of the previous year[2] - Total current assets decreased to ¥321,565,865.07 from ¥383,795,371.88, a decrease of 16.2%[14] - Total non-current assets decreased to ¥2,257,072,925.76 from ¥2,365,660,004.83, a decline of 4.6%[14] - Total liabilities decreased to ¥1,135,727,408.63 from ¥1,331,156,011.12, a reduction of 14.7%[15] - The company's total assets decreased to ¥2,578,638,790.83 from ¥2,749,455,376.71, a decline of 6.2%[15] Shareholder Information - Shareholders' equity attributable to the parent company increased to ¥1,499,954,317.32, a rise of 0.91% year-on-year[2] - The actual controller, Mr. Zhong Hangen, holds 43,342.34 million shares, accounting for 28.75% of the total share capital[12] - The number of ordinary shareholders at the end of the reporting period was 37,392[5] Cash Flow - Cash flow from operating activities was -¥27,440,856.49, an improvement of 6.65% compared to the same period last year[2] - The company's cash and cash equivalents decreased to ¥47,093,603.97 from ¥72,972,604.68, representing a decline of 35.4%[13] - Cash inflow from operating activities was 1,369,415,115.54 CNY, compared to 1,142,940,782.73 CNY in the same quarter last year[19] - The net cash outflow from operating activities was CNY 27,440,856.49, an improvement from CNY 29,395,839.56 in the previous year[20] - Cash inflow from investment activities totaled CNY 52,555,354.74, compared to CNY 38,551,182.69 in the same period last year, resulting in a net cash flow from investment activities of CNY 35,165,567.54, a significant recovery from a net outflow of CNY 3,381,854.52[20] Government and Compliance - The company received government subsidies amounting to ¥153,420.30 during the reporting period[3] - The company reported a total of 4,456.40 million RMB in costs related to the compliance and rectification of various projects as per the exemption agreement[8] - The company has not completed the rectification of the F052 project as per the exemption agreement[8] - The company has completed the transfer or update of 19 out of 24 qualification certificates as required by the exemption agreement[8] Other Financial Metrics - Research and development expenses decreased to 1,121,632.85 CNY from 1,431,752.64 CNY, reflecting a 21.7% reduction[17] - The company recorded an investment loss of -1,094,981.78 CNY, a notable improvement from -30,948,923.23 CNY in the previous year[17] - The basic and diluted earnings per share were both 0.0009 CNY, recovering from -0.0676 CNY in Q3 2023[18] - Other comprehensive income after tax attributable to the parent company was 1,360,284.28 CNY, compared to 1,060,801.86 CNY in the previous year[18] Asset Disposal and Bankruptcy - The company reported a significant increase in asset disposal gains of 15,903.97% due to land disposal by Jiangsu Jialong Company[4] - The company plans to apply for the bankruptcy liquidation of its subsidiary, Jiangsu Jialong Chemical Co., Ltd., following a court ruling[11]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 江苏辉丰生物农业股份有限公司 关于收到民事判决书的公告 证券代码：002496 证券简称：辉丰股份 公告编号：2024-032 导性陈述或重大遗漏。 江苏辉丰生物农业股份有限公司（以下简称"公司"、"辉丰股份"）于近日收到江苏省 高级人民法院出具的《民事判决书》(2021)苏民终2071号，现将有关情况公告如下： 一、案件基本情况 （一）案件当事人 上诉人(原审被告)：江苏辉丰生物农业股份有限公司，住所地：江苏省盐城市大丰区王港 闸南首。 上诉人(原审原告)：刘学颜（张玮配偶）、郑健贤 被上诉人（原审原告）:许光挺、胡军、陈艳琴、肖明忠 （二）案件主要内容 公司、张玮、郑健贤因与被上诉人许光挺、胡军、陈艳琴、肖明忠代表228名投资者证券 虚假陈述责任纠纷一案，不服江苏省南京市中级人民法院(2020)苏01⺠初2891号民事判决，向 江苏省高级人民法院提起上诉。上诉请求及事实与理由详见公司于2021年8月3日在《上海证券 报》、《证券时报》和巨潮资讯网（www.cninfo.com.cn）披露的《江苏辉丰生物农业股份有 限公司关于诉讼事 ...

Financial Performance - The company's operating revenue for the first half of 2024 was ¥110,116,145.93, a decrease of 10.06% compared to ¥122,429,240.24 in the same period last year[10]. - The net profit attributable to shareholders of the listed company was ¥34,759,254.81, showing a significant increase of 171.56% from a loss of ¥48,574,542.40 in the previous year[10]. - Basic and diluted earnings per share were both ¥0.0231, a turnaround from a loss of ¥0.0322 per share in the previous year, reflecting an increase of 171.74%[10]. - The company achieved a gross profit margin of 29.28%, which is a decrease of 2.85% compared to the previous year[23]. - The total comprehensive income for the first half of 2024 was CNY 35,233,971.80, compared to a loss of CNY 50,702,051.69 in the same period of 2023[103]. - The company reported a net profit of approximately 62.43 million yuan, reflecting a significant decrease compared to the previous period[47]. - The company recorded a net profit of 56,758,825.60 for the terminated operations of Jialong Chemical, a significant recovery from the previous year's loss[73]. Cash Flow and Liquidity - The net cash flow from operating activities was negative at ¥1,072,637.97, a decline of 156.10% compared to a positive cash flow of ¥1,912,110.43 in the same period last year[10]. - The total cash and cash equivalents at the end of the first half of 2024 were 23,578,834.93 CNY, down from 70,807,198.12 CNY at the end of the first half of 2023[108]. - The company experienced a net increase in cash and cash equivalents of -26,137,700.26 CNY in the first half of 2024, contrasting with a positive increase of 51,677,517.68 CNY in the same period of 2023[108]. - The company's cash and cash equivalents at the end of the period amounted to ¥44,471,704.48, a decrease from ¥72,972,604.68 at the beginning of the period, representing a decline of approximately 39%[192]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,644,379,615.09, down 3.82% from ¥2,749,455,376.71 at the end of the previous year[10]. - The company's long-term equity investments amounted to ¥978,116,376.56, representing 36.99% of total assets, with no significant changes reported[26]. - The total liabilities decreased from CNY 1,331,156,011.12 to CNY 1,167,339,326.64, a reduction of approximately 12.3%[97]. - The total accounts receivable at the end of the period was ¥224,640,457.51, down from ¥255,908,487.11 at the beginning, indicating a decrease of about 12.2%[195]. Investments and R&D - The company has applied for 18 domestic invention patents, with 11 granted and 5 PCT international patents, focusing on agricultural innovations across 40 countries[16]. - The company reported a significant increase in investment income, reaching CNY 7,790,599.06, up from CNY 6,676,551.83 year-over-year[102]. - Research and development expenses were CNY 822,097.17, slightly down from CNY 887,964.99 in the previous year[102]. Operational Strategy and Risks - The company faces operational risks and has outlined measures to address these risks in the report[1]. - The company is actively entering the green ammonia energy sector, having signed a cooperation agreement with Baowu Clean Energy for ammonia hydrogen energy development[14]. - The company's strategic focus is on "soil health, crop health, and human health," with a commitment to reducing chemical inputs while enhancing agricultural productivity[16]. Shareholder and Corporate Governance - The company plans not to distribute cash dividends or issue bonus shares, indicating a focus on reinvestment[1]. - A total of 383 employees participated in the employee stock ownership plan, holding a total of 30,595,320 shares, which represents 2.03% of the company's total equity[40]. - Key executives maintained their shareholdings during the reporting period, with the largest individual holding being 2,807,266 shares, representing 0.19% of the total equity[41]. Legal and Compliance Issues - The company is involved in a lawsuit with an investor, with a claimed amount of 139.66 million yuan, and has appealed the first-instance judgment[49]. - The company has a pending arbitration dispute with a partner regarding a share purchase agreement, with a claimed amount of 46.92 million yuan[50]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[44]. Market and Product Development - The company launched three new patented products: Nengbaiwang® small molecule functional fertilizer, Nengbaiwang® energy substance, and Nengbaiwang® Abamectin granules, focusing on soil health and crop resilience[14]. - The company emphasizes brand and channel development, establishing a nationwide marketing network and being recognized as a well-known trademark in China[17]. - The company has plans for market expansion and new product development, focusing on enhancing its competitive edge in the agricultural biotechnology sector[117]. Financial Reporting and Accounting Policies - The semi-annual financial report was not audited[94]. - The company adheres to the accounting standards and ensures that its financial statements accurately reflect its financial position and performance[130]. - The company recognizes deferred tax assets and liabilities based on the difference between the book value of assets and liabilities and their tax bases, calculated at applicable tax rates[183].

注1：安道麦股份有限公司为本公司重要联营企业安道麦辉丰(江苏)有限公司、安道麦辉丰（上海）农业技术有限公司之控股股东，故将安道麦股份有限公司及其子公司与公司发生的交易作为本公司的其他关联方进行列示 非经营性资金占用及其他关联资金往来情况汇总表 2024年半年度 其他关联方及其附属企业 | 其他关联方及其附属企业 | 安道麦辉丰(江苏)有限公司 | 联营企业 | 其他应收款 | | | | 往来款 | 非经营性往来 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 安道麦辉丰（上海）农业技术有限公司 联营企业 | | 应收账款 | | | | 货款 | 经营性往来 | | | 安道麦辉丰（上海）农业技术有限公司 联营企业 | | 预付账款 | 182.57 | | | 182.57 货款 | 经营性往来 | | | Profeng Australia Pty.Ltd. | 联营企业 | 应收账款 | 1,055.27 | | 18.15 | 1,037.12 货款 | 经营性往来 | | | Profeng Australia Pty.L ...

为保证监事会正常运作，根据《公司法》、《公司章程》等有关规定，公司 第九届监事会由三名监事组成，其中一名为职工代表监事，由公司职工代表大会 选举产生。公司于 2024 年 8 月 15 日召开职工代表大会，经与会职工代表认真审 议，选举卞宏群先生担任公司第九届监事会职工代表监事（简历附后），与公司 两名非职工代表监事共同组成本公司第九届监事会，任期与公司第九届监事会一 致。 卞宏群先生符合《公司法》、《公司章程》有关监事任职的资格和条件，公 司最近两年内曾担任过公司董事或者高级管理人员的监事人数未超过公司监事 总数的二分之一；单一股东提名的监事未超过公司监事总数的二分之一，公司第 八届监事会中职工代表监事的比例不低于三分之一，符合《公司章程》的规定。 证券代码：002496 证券简称：辉丰股份 公告编号：2024-030 江苏辉丰生物农业股份有限公司 关于选举职工代表监事的公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 2024 年 8 月 15 日 附卞宏群先生简历 卞宏群：男，1976 年 1 月生，中国国籍，无境外永久居留权，本科学历、 会计师、中 ...

本次会议的召集、召开符合《公司法》等法律法规和《公司章程》等制度的规定。 证券代码：002496 证券简称：辉丰股份 公告编号：2024-029 江苏辉丰生物农业股份有限公司 第九届董事会第五次临时会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 江苏辉丰生物农业股份有限公司（以下简称"公司"）第九届董事会于 2024 年 8 月 8 日以通讯方式向公司董事发出关于召开公司第九届董事会第五次临时会议的通知。本次会议 于 2024年 8月 14 日 9：00在公司会议室以现场结合通讯方式召开，全体董事 9 人参加会议， 会议由公司董事长仲汉根先生主持。 2、审计委员会推荐、提名委员会审核意见。 特此公告。 江苏辉丰生物农业股份有限公司董事会 二〇二四年八月十四日 韦广权先生简历： 二、董事会会议审议情况 本次会议以现场结合通讯表决的方式，经与会董事认真审议相关议案，情况如下： 1、审议通过《关于聘任公司审计机构负责人的议案》 经公司审计委员会推荐，提名委员会审核，聘任韦广权先生（简历附后）为公司审计机 构负责人。任期自本次会议 ...